Companies › Outlook Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Ophthalmology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bevacizumab (ONS-5010) Vascular endothelial growth factor A inhibitor | VEGFA | Phase 3 | Age-Related Macular Degeneration | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05112861 | Bevacizumab (ONS-5010) | Phase 3 | Age-Related Macular Degeneration | Ophthalmology | Dec 2027 |
Cash of $11m on 2026-06-30; operating cash outflow about $59m a year; runway about 2 months at that burn, to Sep 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
BioDlink Biopharm Innostellar Biotherapeutics EyePoint Pharmaceuticals Adverum Biotechnologies Alvotech Swiss
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.